Our results link LOXL2 to RBPs’ modulation in breast cancer; thus, using LOXL2 inhibitors in combination with RBP inhibitors may provide a more effective therapeutic strategy for treating breast cancer, as well as circumventing potential issues associated with targeting LOXL2 alone. The gene discussed is LOXL2; the disease is breast carcinoma.